Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study

作者:Delaunay Jacques; Recher Christian; Pigneux Arnaud; Witz Francis; Vey Norbert; Blanchet Odile; Lefebvre Pascale; Luquet Isabelle; Guillerme Isabelle; Volteau Christelle; Gyan Emmanuel; Lioure Bruno; Jourdan Eric; Bouscary Didier; Guieze Romain; Randriamalala Edouard; Uribe Mario E Ojeda; Dreyfus Francois; Lacombe Catherine; Bene Marie christine; Cahn Jean Yves; Harousseau Jean Luc; Ifrah Norbert
来源:53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, 2011-12-10 to 2011-12-13.
  • 出版日期2011-11-18